FDA Issues Emergency Clearance For Covid-19 Drug

Home*Cover Story*News

FDA Issues Emergency Clearance For Covid-19 Drug

The Food and Drug Administration (FDA, “Anvisa of the USA”) has granted emergency authorization for treatment against COVID-19 developed by the Eli Lilly laboratory, reports the New York Times.

The decision, announced on November 9th by the agency, advises to use the drug only in people newly infected with the virus and warns that it should not be used in hospitalized patients.

Eli Lilly said that the drug Bamlanivimab should be administered as soon as possible after a positive test and within 10 days after the development of COVID-19 symptoms.

The treatment was approved for people aged 12 and over who have “tested positive” and are at risk of developing a severe form of COVID-19 or being hospitalized due to the disease.

That includes people over 65 and obese, said the FDA – a key group that, according to the studies, can benefit the most from treatment.

One of the people who received bamlanivimab in the U.S. before the agency’s approval was Chris Christie, a former governor of New Jersey, who is 58 and is in the obese group. He recovered from COVID-19.